Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
BUSINESS
With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
Ole Moelskov Bech, Japan president of Danish diabetes powerhouse Novo Nordisk, said on April 16 that this year’s launch is unlikely for new single-dose devices of its once-weekly GLP-1 agent Ozempic (semaglutide), which are now being developed to comply with…
To read the full story
Related Article
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
- Novo Files Oral Semaglutide in Japan
July 25, 2019
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- Novo’s Ozempic Skips Listing for 3rd Time 8 Months after Approval
November 14, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Novo Japan Renews Sales Record in 2017 as Tresiba, Ryzodeg Gain Ground
April 17, 2018
BUSINESS
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…